Axogen 과거 순이익 실적
과거 기준 점검 0/6
Axogen은 연평균 17.2%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 연평균 13.6%의 비율로 증가했습니다. 매출은 연평균 13.7%의 비율로 증가했습니다.
핵심 정보
17.15%
순이익 성장률
19.74%
주당순이익(EPS) 성장률
| Medical Equipment 산업 성장률 | 8.90% |
| 매출 성장률 | 13.74% |
| 자기자본이익률 | -12.85% |
| 순이익률 | -13.21% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 04
AXGN: BLA Approval And New Market Entry Will Drive Upside Potential
Axogen's analyst price target has been raised from $41.22 to $50.78, with analysts pointing to updated assumptions around fair value, revenue growth, profit margins and recent Street research highlighting the impact of Avance Nerve Graft's BLA approval and commercial expansion opportunities. Analyst Commentary Recent Street research around Axogen clusters around the impact of Avance Nerve Graft's BLA approval, expanded market exposure and revised fair value assumptions, with a series of price target moves anchoring the discussion.분석 기사 • Apr 30
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78
It's been a pretty great week for Axogen, Inc. ( NASDAQ:AXGN ) shareholders, with its shares surging 12% to US$41.77 in...내러티브 업데이트 • Apr 18
AXGN: BLA Approval And Market Expansion Will Shape Balanced Risk Reward Outlook
Narrative Update on Axogen Axogen's updated fair value estimate has moved by about $0.67, with analysts pointing to higher price targets around $40 to $42, supported by Avance Nerve Graft's FDA BLA approval, broader market expansion plans, and recent coverage highlighting its differentiated position in peripheral nerve repair. Analyst Commentary Recent research commentary on Axogen has focused heavily on the FDA BLA approval for Avance Nerve Graft, higher price targets around the low $40 range, and the company’s focus on expanding into new clinical markets.내러티브 업데이트 • Apr 01
AXGN: BLA Approval Will Support Broader Peripheral Nerve Repair Adoption
Narrative Update on Axogen Axogen's analyst price targets have shifted higher into the low $40s, with analysts pointing to recent FDA BLA approval for Avance Nerve Graft, broader market expansion plans, and reduced risk following an equity raise as key supports for their updated views. Analyst Commentary Recent research on Axogen has centered on the FDA BLA approval for Avance Nerve Graft, the equity raise, and the company’s focus on peripheral nerve repair.내러티브 업데이트 • Mar 17
AXGN: BLA Approval Should Support Wider Nerve Repair Market Adoption
Analysts have nudged Axogen's fair value estimate higher, with the blended price target moving from about $39.20 to roughly $40.56 as recent FDA BLA approval for Avance Nerve Graft and broader market expansion potential support more constructive views on growth and profitability. Analyst Commentary Recent research updates cluster around a more constructive view of Axogen following FDA BLA approval for Avance Nerve Graft and a clearer path to broader market coverage and adoption.내러티브 업데이트 • Mar 03
AXGN: BLA Approval And Equity Raise Will Support 2026 Nerve Repair Rollout
Axogen's analyst price target moves higher, with recent Street research pointing to a range of $40 to $42 as analysts highlight the FDA BLA approval for Avance Nerve Graft, expanded market opportunities, and expectations for sustained revenue growth and improving profitability. Analyst Commentary Recent research updates cluster around the FDA BLA approval for Avance Nerve Graft and how it could influence Axogen's growth, profitability, and valuation over time.내러티브 업데이트 • Feb 17
AXGN: Follow On Equity Raises Will Support Bullish 2025 Outlook
Analysts have slightly trimmed their average price target for Axogen, now reflecting a modestly lower assumed future P/E multiple while keeping fair value estimates around $37.33 and making only marginal adjustments to the discount rate, revenue growth, and profit margin assumptions. What's in the News Axogen filed a follow on equity offering of up to $85 million in common stock, providing additional access to equity capital if the company chooses to proceed with the full amount.내러티브 업데이트 • Feb 02
AXGN: FDA Approval And Capital Raises Will Shape 2025 Outlook
Analysts have nudged their price target for Axogen slightly higher to reflect a modest uptick in fair value estimates to about $37.33. This move is supported by marginally stronger assumptions for profit margins and a slightly lower discount rate, while other pricing inputs, such as future P/E expectations, remain roughly in line with prior views.내러티브 업데이트 • Jan 19
AXGN: Q3 Execution And 2025 Outlook Will Support Higher Confidence
Analysts have nudged their fair value estimate for Axogen higher to US$37.00 from US$35.44, citing recent price target increases following Q3 outperformance and raised 2025 guidance as support for this updated view. Analyst Commentary Recent research updates cluster around Axogen's Q3 performance and refreshed 2025 outlook, with multiple price target revisions framing how analysts are thinking about valuation, growth, and execution risk.내러티브 업데이트 • Jan 04
AXGN: Q3 Execution Will Support Confidence In Raised 2025 Outlook
Analysts have nudged their average price target on Axogen higher, lifting it by a few dollars per share into the mid 20 dollar range. They cite the company's Q3 sales beat, increased 2025 growth outlook, and continued confidence in its market development strategy as key drivers of sustained revenue expansion.내러티브 업데이트 • Dec 14
AXGN: Market Development Progress Will Support Confidence In 2025 Outlook
Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.내러티브 업데이트 • Nov 30
AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead
Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.분석 기사 • Nov 27
Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...내러티브 업데이트 • Nov 16
AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook
Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.분석 기사 • Nov 04
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shares have continued their recent momentum with a 30% gain in the last month alone. The...내러티브 업데이트 • Oct 31
AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside
Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.분석 기사 • Sep 12
Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jul 23
Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
Those holding Axogen, Inc. ( NASDAQ:AXGN ) shares would be relieved that the share price has rebounded 29% in the last...새로운 내러티브 • May 29
BLA Approval Will Secure 12-Year Exclusive Market Position
Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.분석 기사 • May 10
Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%
Axogen, Inc. ( NASDAQ:AXGN ) shareholders that were waiting for something to happen have been dealt a blow with a 32...분석 기사 • Apr 17
Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Mar 26
Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Axogen, Inc. ( NASDAQ:AXGN ) is a stock to...분석 기사 • Jan 14
Is Axogen (NASDAQ:AXGN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Jan 07
Axogen: Well Placed To Capitalize Growth At Higher Multiples
Summary Axogen has surged 204% in 12 months, driven by strong sales growth, margin expansion, and efficient capital utilization, offering a favorable risk/reward profile. I get to projected revenues of $280-$350M by FY'26E with NOPAT of $30-$40M, and a valuation range of $22-$28/share, providing 68% upside potential. AXGN's key growth drivers include successful new facility operations, Avance segment progress, and high adoption rates of Axoguard HA and Avive+ products. Read the full article on Seeking Alpha분석 기사 • Dec 24
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shareholders would be excited to see that the share price has had a great month, posting a...분석 기사 • Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely
Despite an already strong run, AxoGen, Inc. ( NASDAQ:AXGN ) shares have been powering on, with a gain of 28% in the...분석 기사 • Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Axogen가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 238 | -31 | 153 | 34 |
| 31 Dec 25 | 225 | -16 | 142 | 33 |
| 30 Sep 25 | 215 | -2 | 129 | 27 |
| 30 Jun 25 | 203 | -5 | 123 | 27 |
| 31 Mar 25 | 195 | -7 | 118 | 26 |
| 31 Dec 24 | 187 | -10 | 117 | 28 |
| 30 Sep 24 | 181 | -14 | 117 | 28 |
| 30 Jun 24 | 173 | -17 | 116 | 28 |
| 31 Mar 24 | 164 | -21 | 116 | 28 |
| 31 Dec 23 | 159 | -22 | 116 | 27 |
| 30 Sep 23 | 152 | -23 | 117 | 27 |
| 30 Jun 23 | 148 | -23 | 116 | 27 |
| 31 Mar 23 | 144 | -25 | 116 | 27 |
| 31 Dec 22 | 139 | -29 | 113 | 26 |
| 30 Sep 22 | 134 | -29 | 113 | 27 |
| 30 Jun 22 | 128 | -32 | 111 | 26 |
| 31 Mar 22 | 127 | -32 | 110 | 25 |
| 31 Dec 21 | 127 | -27 | 106 | 24 |
| 30 Sep 21 | 128 | -28 | 108 | 23 |
| 30 Jun 21 | 131 | -22 | 106 | 21 |
| 31 Mar 21 | 119 | -22 | 99 | 19 |
| 31 Dec 20 | 112 | -24 | 96 | 18 |
| 30 Sep 20 | 108 | -25 | 94 | 18 |
| 30 Jun 20 | 103 | -29 | 95 | 18 |
| 31 Mar 20 | 108 | -28 | 100 | 18 |
| 31 Dec 19 | 107 | -29 | 103 | 18 |
| 30 Sep 19 | 102 | -27 | 97 | 16 |
| 30 Jun 19 | 96 | -26 | 92 | 16 |
| 31 Mar 19 | 90 | -26 | 87 | 14 |
| 31 Dec 18 | 84 | -22 | 80 | 12 |
| 30 Sep 18 | 77 | -20 | 72 | 10 |
| 30 Jun 18 | 71 | -18 | 65 | 8 |
| 31 Mar 18 | 65 | -12 | 58 | 7 |
| 31 Dec 17 | 60 | -10 | 52 | 7 |
| 30 Sep 17 | 55 | -14 | 49 | 6 |
| 30 Jun 17 | 50 | -14 | 46 | 5 |
| 31 Mar 17 | 45 | -14 | 42 | 5 |
| 31 Dec 16 | 41 | -14 | 39 | 4 |
| 30 Sep 16 | 38 | -12 | 36 | 4 |
| 30 Jun 16 | 34 | -13 | 34 | 4 |
| 31 Mar 16 | 30 | -13 | 31 | 4 |
| 31 Dec 15 | 27 | -13 | 29 | 3 |
| 30 Sep 15 | 24 | -16 | 26 | 3 |
| 30 Jun 15 | 21 | -16 | 23 | 3 |
양질의 수익: AXGN 은(는) 현재 수익성이 없습니다.
이익 마진 증가: AXGN는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: AXGN는 수익성이 없지만 지난 5년 동안 연평균 17.2%의 속도로 손실을 줄였습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 AXGN의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: AXGN은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: AXGN는 현재 수익성이 없으므로 자본 수익률이 음수(-12.85%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/24 09:03 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Axogen, Inc.는 18명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Christopher Pasquale | Guggenheim Securities, LLC |